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About 30 members of tumor necrosis factor receptor superfamily (TNFRSF) have been 
identified. They are transmembrane proteins with cysteine-rich motifs in their extracellular 
domains that bind to their cognate ligands [1]. They are categorized into three groups; death 
domain-containing receptors, decoy receptors, and TNF receptor-associated factor-binding 
receptors. Only eight TNFRSF members contain a death domain (TNFR1, DR3, DR4, DR5, 
DR6, Fas, NGFR, EDAR) of which TNFR1 and DR3 constitute the principle focus of this 
article. Interactions between tumor necrosis factor superfamily (TNFSF) ligands and TNFRSF 
receptors help maintain tissue homeostasis by controlling survival, proliferation, differentiation, 
and effector function of immune cells. Here the authors limit their review to recent advances and 
novel insights into the role of TNFR1 and DR3 in bone and joint biology.  
Bone cells (osteoblasts, osteoclasts and osteocytes), fibroblast-like synoviocytes, chondrocytes 
and immune cells that infiltrate the arthritic joint will at different times express a wide range of 
TNFRSF members and TNFSF ligands. An overview of the current status of our knowledge in 
this regard is provided in Table 1.  The impact of TNFR1 activation on bone and inflammatory 
joint diseases has been researched in great depth [2, 3], but other more recently discovered 
TNFRSF members such as TROY, EDAR and XEDAR have little or no published data in the 
field.  The unexpected interaction between Progranulin (PGRN) and both TNFR1 and TNFR2 is 
particularly interesting in the context of arthritis-associated bone pathology. PGRN levels are 
elevated in synovial fluid of patients with rheumatoid arthritis, osteoarthritis and other 
arthropathies [4-6], and it has been shown to inhibit TNFα-induced osteoclastogenesis and 
promotes osteoblast differentiation in mice [7]. However, PGRN has a higher binding affinity for 
TNFR2 (anti-inflammatory with osteoprotective function) than TNFR1 (predominantly pro-
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inflammatory with degenerative function) suggesting conflicting actions. The potential overall 
impact of these divergent PGRN signaling pathways upon the architecture of the arthritic joint 
are evaluated  [8].  
Death receptor (DR3) and its TNFSF ligand TL1A contribute to the pathogenesis of autoimmune 
and rheumatic diseases [9], however, research in this area is very much in its infancy. Inhibition 
of DR3 reduces osteoclastogenesis and protects bones against the development of erosive 
pathology in experimental models of arthritis [10]. A soluble form of DR3, produced by 
osteoblasts, regulates osteoblast apoptosis under tightly controlled conditions [11, 12]. TL1A 
levels are elevated in serum from patients with rheumatoid arthritis versus healthy controls. This 
review provides further insight to DR3’s role in bone remodeling and arthritis.  
 
PGRN/TNFR interactions in arthritis and bone remodeling 
PGRN, also known as granulin–epithelin precursor (GEP), proepithelin, acrogranin, and 
GP88/PC-cell derived growth factor (PCDGF), is a 593-amino-acid autocrine growth factor. 
PGRN contains seven-and-a-half repeats of a cysteine-rich motif (CX5–
6CX5CCX8CCX6CCXDX2HCCPX4CX5–6C) and forms a unique “beads-on-a-string” 
structure [13]. PGRN was first found to bind to TNFR in a yeast two-hybrid screening for 
PGRN-binding proteins[14]. The interaction was subsequently validated in human cells. Surface 
plasmon resonance (SPR) analysis revealed that PGRN bound to both TNFR1 and TNFR2 and 
with greater affinity than TNFα to TNFR2 [8, 14]. Three fragments of PGRN and their adjacent 
linkers enable the ligand to bind to TNF receptors [15]. Notably, PGRN showed therapeutic 
effects in several TNF-mediated inflammatory arthritis models, including collagen-induced 
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arthritis, collagen antibody induced arthritis, and spontaneous arthritis in the TNF-transgenic 
mouse model [14, 16, 17]. Furthermore a novel PGRN-mimetic called Atsttrin (Fig. 1) had a 
more pronounced beneficial effects than PGRN on inflammatory arthritis [14]. Currently 
marketed anti-TNF therapies bind to the TNFα ligand, in contrast, Atsttrin binds to TNFR and 
not to TNFα itself. Atsttrin was more efficacious than current anti-TNFα therapies, including 
etanercept, in several preclinical inflammatory arthritis models tested [14]. 
Accumulating evidence indicates that TNFα orchestrates osteoarthritis (OA) pathology [18]. 
Recent finding support the notion that PGRN could also modulate the aetiopathogenesis of OA. 
PGRN is an important regulator of cartilage development [19, 20], was identified as an OA-
associated growth factor in a genome-wide screen for differentially expressed genes in OA [21], 
and in aging mice PGRN deficiency led to spontaneous OA-like phenotype characterized by 
severe breakdown of cartilage structure[22]. The OA-like pathology was attenuated by the local 
delivery of a recombinant PGRN protein. Intra-articular transplantation of Atsttrin-transduced 
mesenchymal stem cells inhibited TNFα-mediated catabolic response, ameliorating OA 
development [23]. One chondro-protective mechanism has been proposed, namely that PGRN 
increased the levels of anabolic biomarkers and suppresses inflammatory action of TNFα in 
cartilage and chondrocytes via activation of the ERK1/2 signaling pathway[19].  
The direct impact of PGRN upon bone remodeling is yet to be determined, with current 
knowledge derived from a bone-healing model. In mice at least, PGRN deficiency delayed bone 
healing, while recombinant PGRN enhanced bone regeneration [24]. Furthermore, PGRN-
mediated bone formation was dependent upon TNFR2, but not TNFR1. In this same study, Zhao 
et al showed that PGRN blocked osteoclastogenesis in TNF-α transgenic mice. Taken together 
these findings imply that PGRN exerts dual action on bone during inflammatory arthritis namely; 
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inhibiting TNF-α induced bone erosion by osteoclasts and promoting osteoblast-dependent 
mineral apposition via a TNFR2.  A recent report using Atsttrin, incorporated into 3D-printed 
alginate/hydroxyapatite scaffolds, implies that PGRN stimulates bone regeneration by inhibiting 
TNF signaling [25]. 
TNFα's inflammatory and catabolic actions are largely mediated through its interaction with 
TNFR1. However, understanding of the impact of TNFR2-mediated signaling remains largely 
unclear. Recent studies indicate that TNFR2 signaling has a beneficial and protective role in joint 
destruction [26, 27]. Studies also reveal differential roles of TNFR1 and TNFR2 in PGRN-
mediated fracture healing and OA[22, 24, 28]. Although PGRN and TNFα exhibit comparable 
binding affinity to TNFR1, PGRN has an approximately 600-fold higher binding affinity for 
TNFR2 than TNFα[14]. Since PGRN and TNFα compete for binding to the same extracellular 
cysteine-rich domains (CRD) of TNFR, CRD2 and CRD3 [8], PGRN acts as a naturally-
occurring antagonist of TNFα and disturbs the binding of TNFα to TNFRs. More importantly, 
PGRN also acts as a ligand of TNFR2 and directly activates the PGRN/TNFR2 protective and 
anti-inflammatory pathway. TNFR2 has been shown to be critical for PGRN-mediated protection 
in OA and bone fracture healing [22, 24, 28]. Recent paper showing that local injection of 
soluble TNFR2 (sTNFR2, etanercept) resulted in more severe joint destruction in a mouse model 
of OA [29] also suggest the importance of PGRN-mediated protection in OA. Injection of 
sTNFR2 inhibits both TNFα and PGRN. Further, PGRN may be more inhibited than TNFα, as 
PGRN has a much higher binding affinity to TNFR2 than TNFα. Unlike etanercept, mouse 
TNFα monoclonal antibody (infliximab) and humanized TNFα monoclonal antibody 
(adalimumab) are specific for TNFα, and have been shown to be protective against OA in animal 
models [30]. The opposite effects of TNFα specific (i.e. infliximab and adalimumab) and non-
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specific (i.e. etanercept) inhibitors in OA indicate the critical protective role of other ligand(s) of 
TNFR, i.e. PGRN, in the pathogenesis of OA [31]. Thus, future studies are warranted to clarify 
the complex interplay between TNFα, PGRN and their receptors in the pathogenesis of arthritis 
and bone remodeling, which will not only better our understanding of TNFR signaling in the 
pathogenesis of these musculoskeletal disorders, but may lead to innovative therapies via 
selectively targeting distinct TNFR pathways.  
 
TL1A/DR3 interactions in arthritis and bone remodeling 
Death Receptor 3 (DR3, TNFRSF25, Apo3, LARD, TR3, TRAMP, WSL-1) was discovered 
simultaneously in the mid-to-late 1990s by multiple groups, when a combination of BLAST 
homology searches to Fas and TNFR1 [32, 33] and a yeast-two hybrid library screen using a 
TNFR1 death domain as bait [34], identified a closely related protein. Subsequently, DR3 
emerged as the closest structural homolog to TNFR1, containing an equivalent 4 CRDs as well 
as an intracellular death domain. Unlike TNFR1, however, whose cellular distribution is 
widespread and surface expression of which is controlled by the generation of soluble forms 
through cleavage, DR3 has a more restricted tissue distribution and is regulated by the 
expression of multiple activation-induced splice variants, including soluble and death-domain 
containing transmembrane forms with excision of the membrane proximal CRD [33, 35]. The 
exact function of these splice variants remain unclear.  
The identification of ligand(s) for DR3 has been complicated by the number of potential 
candidates and their altering nomenclature [36], but prior to the discovery of PGRN, one TNFSF 
member, TNF-like protein 1A (TL1A, TNFSF15) [37], had withstood stringent biochemical and 
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functional scrutiny for DR3 specificity [38, 39]. TL1A is the product of a longer alternative 
mRNA transcript to a protein initially named vascular endothelial growth inhibitor or VEGI 
(TL1), so named for its capacity to inhibit angiogenesis and induce apoptosis of endothelial cells 
[40]. As its name and nomenclature suggests, TL1A is closely related in structure to TNFα, 
encoding a type II transmembrane protein with a metalloprotease cleavage site allowing release 
of a soluble molecule, but also has distinct expression patterns as it is found in ng/ml 
concentrations in serum from healthy individuals [41] that suggests physiologically different 
levels of production and functional regulation. In this regard, there may also be significant 
differences between species as DcR3, the decoy ligand for TL1A, FasL and LIGHT (discussed 
above), is only found in man and not mouse. It is in this context that interpretations of DR3 
function and its potential for therapy should be taken. 
The generation of transgenic mice genetically deficient for DR3, TL1A or overexpressing TL1A  
or dominant negative forms of DR3 have given rise to many in vivo studies describing the 
essential requirement for the DR3/TL1A pathway in models of multiple autoimmune and 
inflammatory diseases. These have supported an ever-growing list of in vitro human functional 
and genetic studies that have associated DR3 and TL1A with human diseases ranging from 
inflammatory bowel disease and primary billiary cirrhosis to leprosy (comprehensively reviewed 
in [42]). Of significance for this review were findings that suggested alternate respective ligands 
for DR3 and TL1A. This included the apparent greater protection against experimental 
autoimmune encephalomyelitis afforded by DR3-/- [38] compared to TL1A-/- mice [43] in 
otherwise similar models of disease and the DR3-independent triggering of TNFR2 expression 
by TL1A in kidney organ cultures [44]. The underlying conclusion was that there were still 
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unknown interactions for this complex of proteins, which will have to be discovered and 
dissected in detail before their full potential as therapeutic targets can be understood. 
With specific regard to disorders of the bone, initial genetic studies suggested DR3 gene 
duplication [45] and a mutation predicted to destabilize DR3 [46] were linked to development of 
rheumatoid arthritis (RA), while synovial cells from RA patients exhibited a hypermethylated 
DR3 gene suggestive of activation [47], however, genome wide association studies (GWAS) 
have had less success with supporting this connection. Two early investigations associated 
genetic variation around the DR3 (TNFRSF25) locus with RA [48, 49], but more recent ones 
have not. In contrast, genetic variation at the TL1A (TNFSF15) locus has not been associated 
with RA, but has been linked to another bone disorder, ankylosing spondylitis [50]. Irrespective, 
increased levels of TL1A have been reported in the serum of patients suffering from both of 
these arthritides [41, 51, 52], as well as the synovial tissue and synovial exudates of rheumatoid 
factor positive RA patients [53, 54]. 
The functional consequences of raised TL1A levels in these disorders have generally been 
associated with a range of outcomes dependent on the type and differentiation state of the DR3-
expressing cell to which TL1A is binding and signaling. Here, we will cover those cell types 
specifically associated with bone physiology irrespective of the inflammatory context, although 
it should be noted that there may also be secondary effects as TL1A can induce TNFα [55], 
thereby having the capacity to trigger a broad range of secondary effects associated with other 
pro-inflammatory cytokines. The DR3/TL1A axis was first described as a T cell co-stimulator 
[37], but its effects on Th17 cells, drivers of osteoclastogenesis and therefore inflammatory bone 
resorption [56], highlighted the complexity in the outcome of TL1A signaling. Initial reports in 
TL1A-/- mice suggested that TL1A regulated Th17 differentiation [43], but more extensive in 
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vitro studies in both DR3-/- mice [57] and healthy human subjects indicated that Th17 
differentiation from naïve CD4+ T cells was impaired, while maintenance of the response once T 
cells were Th17 committed was enhanced, by TL1A [58]. Intriguingly, recent reports have 
shown that TL1A-driven Th17 differentiation from naïve CD4+ T cells occurs in samples from 
RA patients [52, 59]. Why these differences have been observed remain an area of debate, 
though the underlying theme is that TL1A promotes the Th17 response in RA. 
The development of the main effectors of bone resorption, osteoclasts, are also regulated by the 
DR3/TL1A axis, at least in an inflammatory setting. While osteoclastogenesis driven by M-CSF 
and RANK-L was unaffected in DR3-/- mice, these animals exhibited resistance to cartilage 
destruction and bone erosions in a model of antigen-induced arthritis (AIA) [39, 60]. 
Furthermore, DR3-/- mice were resistant to exacerbation induced by exogenous addition of 
TL1A, while antagonism of the pathway with anti-TL1A mAb ameliorated disease in collagen-
induced arthritis (CIA) [39]. Addition of exogenous TL1A also exacerbated CIA [54]. The direct 
nature of this signaling in myeloid cells has been demonstrated, with DR3 expression being 
induced during the process of macrophage differentiation and TL1A signaling resulting in the 
DR3-dependent production of the gelatinase MMP-9 [61]. The DR3/TL1A pathway may also 
control other aspects of macrophage differentiation that promote the arthritic process. Thus, DR3 
regulates the expression of scavenger receptors on macrophages [62], which have been 
implicated in AIA-induced cartilage destruction [63].  
Finally, DR3 also modulates osteoblast function. Human osteoblast cell lines were first reported 
to express DR3 in 2003 [64], which were then used to demonstrate differential regulation 
dependent on cell culture conditions. Crosslinking induced apoptosis at low density, but 
differentiation at high density [11]. The subsequent reported association between TL1A and 
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ankylosing spondylitis [50] and breeding of the DR3-/- genotype on a DBA/1 background, which 
spontaneous develops ankylosing enthesopathy [65], led to a recent study on the role of DR3 in 
osteoblast function in vitro and in vivo. Indeed, DBA/1 DR3-/- mice showed significantly lower 
thoracic spine-specific bone formation in vivo, while DR3-/- osteoblast cultures exhibited reduced 
levels of alkaline phosphatase, osteopontin and mineral apposition [12]. Thus, the DR3/TL1A 
axis is involved in the direct regulation of every major cell type involved in bone physiology, 
recent data suggesting it has an important homeostatic role in this tissue as well as its more 
established function in inflammatory disease.  
 
PGRN/DR3 Interactions in arthritis and bone remodeling 
Screening the associations of Atsttrin with all members of the TNFR subfamily led to the 
discovery that in addition to TNFR, PGRN/Atsttrin also directly binds to DR3 and inhibits TL1A 
activity [66]. Structural modeling of DR3 predicts a similar structure to TNFR1 in which primary 
contacts with TL1A are in the 2nd and 3rd CRD [46]. In addition, a mutation linked to rheumatoid 
arthritis at the end of CRD3 is in a region critical for structural integrity of ligand–receptor 
complexes [46]. The first three CRD domains of the extracellular potion of DR3, i.e. CRD1, 
CRD2 and CRD3, are all required for interacting with Atsttrin. PGRN was also found to directly 
bind to DR3 in an in vitro binding assay, as it did to TNFRs [66]. Atsttrin dose-dependently 
inhibited TL1A-stimulated expressions of TL1A-target genes C1qTNF3 and βigH3. In addition, 
Atsttrin effectively neutralized TL1A-promoted osteoclastogenesis in vitro[66].  
The associations of PGRN with TNFR and DR3 also led to investigations on the immunological 
mechanisms underlying PGRN mediated anti-inflammatory and protective activities in 
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autoimmune diseases[67-69]. Since both animal and human studies have demonstrated that 
regulatory T cells (Tregs) play a critical role in the prevention of autoimmunity and other 
pathological immune responses, the effects of PGRN on Treg differentiation and function were 
first determined. PGRN protects Tregs from a negative regulation by TNFα and these protective 
effects are primarily mediated by TNFR2[68, 69]. In contrast, PGRN-antibodies, opposite to 
recombinant PGRN, led to an increase of TNFα-induced down-regulation of FOXP3 in 
CD4+CD25hi Tregs [70]. In addition, PGRN was able to stimulate the conversion of CD4+CD25-
T cells into induced Tregs (iTregs) in a dose-dependent manner in vitro. Further, PGRN showed 
synergistic effects with TGF-β1 on the induction of iTreg[69]. PGRN was required for the 
immunosuppressive function of Tregs, since PGRN-deficient Tregs have a significant decreased 
ability to suppress the proliferation of effector T cells. PGRN deficiency caused a marked 
reduction in Tregs number in the course of inflammatory arthritis [69]. In a bone marrow 
chimera and CD4+CD45Rbhi T cell transfer model, lack of PGRN signaling in CD4+ T cells also 
exacerbated experimental colitis. In addition, PGRN-mediated protective effect was 
compromised in the absence of IL-10 or TNFR2 signaling[68]. It is noted that PGRN mediated 
regulation of Tregs appears to be inflammation-dependent, because PGRN deficiency does not 
alter the numbers of CD4+CD25+Foxp3+ Treg cells in vivo under physiological conditions [69]. 
Progranulin inhibits expression and release of chemokines CXCL9 and CXCL10 in a TNFR1 
dependent manner CD4+ T cells [67]. The DR3 pathway may also contribute to PGRN-mediated 
protective effect in inflammatory diseases, since a recent report showed that agonistic antibody 
to DR3 expanded CD4(+)FoxP3(+) Tregs in vivo, which in turn suppressed immune responses. 
In addition, a neuropathology develops with age in both DR3-/- [71] and PGRN deficient 
mice[72].  Intriguingly, transgenic overexpression of TL1A in both the myeloid and T cell 
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lineage results in in vivo expansion of Tregs, though these eventually become dysregulated and 
intestinal inflammation develops [10]. 
 
In contrast to Tregs, Th17 cell frequency was decreased significantly in the spleens of mice 
treated with recombinant PGRN in a collagen-induced arthritis model[68, 69]. In addition, the 
serum level of IL-17 was also decreased significantly in PGRN-treated mice. Further, both 
TNFR1 and DR3 pathways were found to be involved in the PGRN inhibition of IL-17 cells. 
Taken together, PGRN and its derived Atsttrin appear to exert their anti-inflammatory activities 
through multiple pathways: 1) by activation of PGRN/TNFR2 protective pathway, and 2) by 
inhibition of TNF/TNFR1 and TL-1A/DR3 inflammatory signaling (Fig. 2).  
  
Clinical perspective 
Because TNFα is one of the key main inflammatory mediators, it is no surprise that alterations of 
its physiologic antagonist PGRN have a direct impact on the initiation and progression of 
arthritis.  The effect of TNFα antagonism should be at least comparable to conventional TNFα-
blockers [14]. The additional specific inhibition of the TL1A/DR3 interaction and activation of 
TNFR2 anti-inflammatory pathway by PGRN or its derivate [66] is a unique characteristic and 
might represent a significant advantage over conventional TNFα inhibitors particularly for 
patients with refractory or relapsing disease under conventional TNFα-blockers. Blocking the 
TL1A/DR3 interaction probably offers additional positive effects by the reduction of 
proinflammatory cytokines, reduction of autoantibody formation and by the reduction of 
osteoclastogenesis [10, 54]. 
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A potential disadvantage of PGRN or Atsttrin compared to anti-TNFα antibodies might be, that 
anti-TNFα antibodies can trigger apoptosis of proinflammatory T-lymphocytes by binding to 
membranous TNFα. This effect, which is also missing for TNFR/Fc fusion proteins, appears to 
play a particular role in inflammatory bowel diseases (IBD) and less in arthritis [73]. The 
question is whether the administration of PGRN or a derivative thereof has a higher risk of 
iatrogenic induced neoplasms than conventional TNFα blockers. Usage of conventional TNFα-
blockers results in an elevated risk for reactivation of latent infections such as mycobacteria, 
viral hepatitis, or for the development of opportunistic infections [74]. The effects of 
administered recombinant PGRN or its derivative on the risk for opportunistic infections remain 
speculative and are not further discussed in this review. 
Another question arises through the discovery of progranulin-autoantibodies: Can recombinant 
PGRN or Atsttrin be administered to patients with preexisting PGRN-antibodies?  Frequently 
occurring PGRN antibodies have been identified in a wide spectrum of autoimmune diseases 
including rheumatoid arthritis and surprisingly psoriatic arthritis, which had been regarded as a 
seronegative disease [5, 75]. PGRN-antibodies occur in relevant titres, belong predominantly to 
IgG1 subclass (in IBD also IgA), have a neutralizing effect on PGRN plasma levels and thus are 
likely to act in a proinflammatory fashion. 
Epitope mapping identified a binding region within the N-terminal 112 amino acids of PGRN as 
a target of progranulin antibodies in all patients. This means that PGRN-autoantibodies target the 
anti-inflammatory progranulin and possibly co-target only mature granulin G, the most N-
terminal granulin motif. Despite the structural similarity of granulin G with the other six 
granulins, no binding against granulin motifs other than granulin G was detected [75]. With 
regard to Atsttrin, no antibodies were detected so far directed against those parts of progranulin 
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which are constitutive of Atsttrin, i.e. granulin F, granulin A, granulin C and the appropriate 
linker regions [14]. Nevertheless, epitope spreading and immunogenicity should be monitored 
closely in preclinical and clinical trials addressing the therapeutic effects of Atsttrin 
administration. A potential binding of patient derived, preexisting PGRN-antibodies against 
Atsttrin itself has not yet been tested to our knowledge and should be excluded.  
As a reason for the breakdown of self-tolerance against PGRN, a second immunogenic PGRN 
isoform, hyperphosphorylated at Ser81 was exclusively identified in a PGRN-antibody-positive 
patients [76]. This hyperphosphorylated PGRN is caused by inactivated PP1. Interestingly, the 
phosphorylation of Ser81 PGRN prevents interaction with TNFR1 & 2 and DR3, so 
hyperphosphorylated PGRN has lost its anti-inflammatory function. Considering these facts, it 
seems a reasonable therapeutic strategy would be to compensate the imbalance of pro- and anti-
inflammatory molecules due to either lack of functional PGRN, caused by neutralizing PGRN-
antibodies, Ser81 hyperphosphorylation of PGRN, and/or excessive secretion of TNFα and 
TL1A, by the administration of a PGRN derivate, which cannot be neutralized by pre-existing 
PGRN-autoantibodies (Fig. 3). 
In conclusion it can be stated that PGRN and its interaction with TNFα/TNFR1&2 and 
TL1A/DR3 represent an attractive new therapeutic target (Table 2). Looking at the underlying 
theory and the known preclinical data, Atsttrin could be a therapeutic alternative in cases of 
refractory or recurrent arthritis. 
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Table 1 Cellular expression of death domain containing TNFRSF members 
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Table 2 Summary of key points about Progranulin and TNFR and DR3 pathways in 
rheumatoid arthritis, osteoarthitis,  spondyloarthritis and other arthropathies 
# Key points References 
1. Progranulin (PGRN) 
• also known as granulin–epithelin precursor (GEP), proepithelin, 
acrogranin, and GP88/PC-cell derived growth factor (PCDGF) 
• 593-amino-acid autocrine growth factor 
• seven-and-a-half repeats of a cysteine-rich motif  
• Involved in: embryogenesis, wound healing antiinflammatory, host 
defense, neurotrophic factor  
• High PGRN levels associated with several human cancers  
 
[14, 16, 17] 
2. PGRN ligand of TNFR1, TNFR2 and DR3 
• PGRN ligand of TNFR1, TNFR2 and DR3 and physiologic antagonist of 
TNF-α, LTα and TL1a 
• Inhibition of TNFR1 and DR3 pathways, but activation of TNFR2 
pathway by PGRN 
• 600 times higher affinity towards TNFR2 by PGRN compared to TNF-α 
• PGRNs affinity to TNFR1, TNFR2 and DR3 originates from granulins F, 
A and C with linker regions 
• Atsttrin: smallest recombinant derivate of PGRN synthesized of 
granulins F, A, C and linker regions P3, P4 and P5 of PGRN with 
preserved antiinflammatory effect 
• PGRN attenuates TNF-α induced downmodulation of CD4+CD25hi 
FOXP3+ Tregs  
• PGRN stimulates conversion of CD4+CD25- T cells into induced Tregs 
(iTregs) 
 
[14, 66, 69] 
3. PGRN, TNFR1 and TNFR2 in Osteoarthritis  
• low PGRN levels -> spontaneous OA 
• high PGRN levels -> anabolic function 
• catabolic effect of TNF-α mainly mediated via TNFR1 
• TNFR2 pathway anti-inflammatory & osteoprotective 
• administration of sTNFR2/Fc fusion protein neutralizes TNF-α and 
PGRN and leads to exageration of OA 
• administration of Anti-TNF-α Mabs neutralizes TNF-α specifically and 
ameliorates OA 





• High levels of TL1A induce TH17 response in RA 
• DR3-/- mice resistant of cartilage destruction in AIA 
• CIA exaggeration by TL1a, amelioration by Anti-TL1a Mab 
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• DcR3 decoy ligand for TL1A, FasL and LIGHT not in mice -> results 
from mouse models difficult to translate 
 
5. pSer81 PGRN and PGRN antibodies 
• Neutralizing PGRN antibodies directed against the N-terminal 112AA 
occur frequently in various autoimmune diseases 
• PGRN antibodies are induced by a second, transiently occuring 
hyperphosphorylated PGRN isoform (pSer81 PGRN) 
• pSer81 PGRN lacks affinity for TNFR1, TNFR2 and DR3 and thus 
antagonism of TNF-α  and TL1a 
• -> dysbalance of proinflammatory TNF-α & TL1A and antiinflammatory 
functional PGRN in various inflammatory disesases  
 
[5] [75, 76] 
6. Clinical Perspective 
• Targeting of TNFR/TNF superfamily common therapeutic strategy 
• Possible advantages of rec. PGRN/Atsttrin compared to conventional 
TNF-blockers due to additional inhibition of DR3 and activation of 
TNFR2 
• PGRN-autoantibodies regularly target the N-terminal 112 AA  and thus 
not the parts constitutive for Atstrrin; however affinity has not been 
excluded 
• Risk of side effects concerning susceptibility to infectious diseases, 
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Fig. 1. A) Domain Structure and Organization of PGRN and Atsttrin. PGRN consists of 7½ 
repeats of a cysteine-rich granulin motif in the order of P-G-F-B-A-C-D-E, where A to G are full 
repeats, and P is the half motif. Atsttrin, derived from PGRN, consists of three half units of 
granulins A, C and F, and their accompanying linker regions. B) A proposed models for 
explaining the independent action of three TNFR-binding domains of PGRN. TNFα trimmers 
binds to receptors in a heterohexameric 3:3 complex[88]. The three fragments of Atsttrin act 
independently for interacting with TNFR, and changing the order of these fragments does not 
affect the ability to binding to TNFR[15]. It is proposed that each TNFR-binding domain may 
function as a single TNFα molecule, and the intact Atsttrin might resemble a TNF trimer through 
internal folding at their linker regions. 
Fig. 2. A proposed model illustrating the multiple signaling pathways by which PGRN (and its 
derivative Atsttrin) exerts its protective actions in autoimmunity. PGRN (Atsttrin) binds to TNF 
receptor 2 (TNFR2) and stimulates the formation and function of Tregs, but may antagonize 
TL1A/DR3 signaling in these cells. PGRN (Atsttrin) also antagonizes TNF/TNFR1 and 
TL1A/DR3 signaling and inhibits their inflammatory activities.  
Fig. 3. A) Balance of TNF-α & TL1A and their antagonist progranulin in a healthy control. B) 
Dysbalance of proinflammatory TNF-α & TL1A and antiinflammatory PGRN due to 
overexpression of proinflammatory TNF-α & TL1A and diminished antagonistic effects of 
PGRN due to hyperphosphorylation of Ser81 of PGRN and induction of neutralizing PGRN-
antibodies. 
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